Further providing for legislative purpose, for definitions, for lead poisoning prevention, assessment and testing and for blood lead assessment and testing coverage.
SB850 amends Pennsylvania’s Childhood Blood Lead Test Act to make childhood lead screening more mandatory and more clearly covered by insurance. The bill changes the stated legislative purpose from encouraging lead testing of all children by age two to requiring it, and it revises the testing provisions so health care providers must make reasonable efforts to ensure a child receives at least one blood lead test by 24 months of age, or by age 72 months if the child has never been tested. It also keeps the requirement for confirmatory testing when a capillary test shows an elevated blood lead level, but ties that confirmation to CDC recommendations rather than the prior fixed 12-week timeline.
The bill also updates insurance coverage rules for blood lead tests. It requires health insurance policies and certain government programs to cover one blood lead test per pregnancy when a CDC risk factor is present, and at least one test for children under age two by 24 months, or for children ages 24 through 72 months if they have never been tested. Covered blood lead tests may not be subject to cost-sharing, meaning no deductibles, copayments, or coinsurance may be charged for those tests. The bill also adds a definition of “cost-sharing” and adjusts effective-date provisions for different types of insurance policies.
In practical terms, SB850 would strengthen statewide lead screening requirements for young children and pregnant individuals and expand the financial protections around those screenings. It would affect health care providers, insurers, government health programs, children under age six, and pregnant patients by making lead testing more routine and removing out-of-pocket costs for covered tests. The bill also aligns several provisions more closely with CDC guidance.
Because there are no committee transcripts or recorded votes in the provided material, there is no documented debate or formal vote history to gauge support or opposition. Based on the bill text alone, the measure appears to be a public-health-focused update intended to improve early detection of lead exposure and reduce barriers to testing. The main policy tension is between stronger mandatory screening and the prior more flexible, recommendation-based approach, especially where provider obligations and insurance mandates are expanded.
SB850 would amend the Childhood Blood Lead Test Act to impose stronger lead-testing expectations on health care providers and to require broader insurance coverage for blood lead tests. It would change the law’s purpose statement, add a definition of cost-sharing, require reasonable efforts to ensure testing by age 2 or by age 6 if never tested, and prohibit cost-sharing for covered blood lead tests. It also updates confirmatory testing and coverage language to reference CDC recommendations, affecting providers, insurers, government programs, and families with young children or pregnant patients.
No committee discussion or vote record was provided, so there is no direct evidence of legislative sentiment from hearings or roll calls. The bill’s text suggests a generally pro-public-health, pro-prevention approach with an emphasis on early detection of lead exposure and reducing financial barriers to testing. The overall tone is preventive and supportive of expanded screening.
The main point of contention implied by the bill is the shift from encouraging lead testing to requiring it, which increases obligations on health care providers and may raise concerns about implementation, compliance, and parental consent. Another likely area of debate is the insurance mandate, especially the prohibition on cost-sharing for covered blood lead tests, which shifts costs to insurers and potentially to the broader premium pool. The bill also narrows some prior references to specific professional recommendations and replaces them with CDC-based standards, which may be viewed as either clarifying or limiting provider discretion.